Metsera, a Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity, raised $275 million by offering 15.3 million shares at $18, above the range of $15 to $17. The company offered 1.9 million fewer shares than anticipated.
Metsera is focused on developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. Its most advanced candidate, MET-097i is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA for the treatment of obesity and overweight. The company has initiated a Phase 2b trial of MET-097i assessing safety and efficacy at different weekly doses in participants with obesity or overweight without type 2 diabetes, and it expects to report preliminary data from this trial in mid 2025. It plans to separately initiate a Phase 2b study in participants with obesity or overweight with T2D.
Metsera plans to list on the Nasdaq under the symbol MTSR. BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, and Cantor Fitzgerald acted as joint bookrunners on the deal.
